7 results about "Bordetella sp" patented technology

The present disclosure relates to the technical field of medicine, and in particular to a pharmaceutical composition, preparation method and use thereof. The pharmaceutical composition includes a first active ingredient, a second active ingredient, and a pharmaceutically acceptable carrier or excipient. The first active ingredient is a microbial agent, including one or more of Staphylococcus aureus, Bordetella pertussis, diphtheria toxoid, tetanus toxoid, Salmonella typhi, and Salmonella paratyphi. The second active ingredient includes polyinosinic acid, polycytidylic acid, and vitamin. The pharmaceutical composition of the present disclosure pertains to an artificial active immunotherapy for tumors. It can “stimulate” the entire immune system, making the therapy of using bacteria to activate the human immune system to kill cancer cells highly stable and reliable. This composition can significantly save and prolong the lives of cancer patients while exhibiting extremely high safety, minimal toxic side effects, and low production costs.

To provide a method for Bordetella fermentation and virulence factor production, especially PT production, for large-scale production, and in particular, to provide a method for medium adaptation performed before inoculation.SOLUTION: A method of producing a conditioned growth media comprising the steps of a. providing a sterile growth media; b. holding the sterile growth media at a temperature between about 28 to about 35 °C. for about 20 to 35 hours; and c. agitating and / or aerating the sterile growth media to generate a volumetric oxygen transfer coefficient (kLa) of about 10h-1 to about 130h-1, thereby providing a conditioned growth media.SELECTED DRAWING: Figure 1

Recent evidence accumulating over the last decade demonstrates that generation of CD4+ T cells is critical for sustained immunity against Bordetella pertussis. B. pertussis contains hundreds of antigens that are processed and presented on MHC Class II and recognized by CD4′T cells. The present disclosure relates to a vaccine comprising Bordetella pertussis antigen peptides to prevent infection of the Bordetella pertussis bacterium.

The present invention relates to culture media and methods for cultivating Bordetella bacteria, particularly for producing vaccines. In particular, the inventors investigated the effects of temperature and alkaline earth metals and transition metals compositions on the growth and virulence factor production of B. pertussis and B. bronchiseptica. They found that both bacteria grew better and expressed more antigens when cultured in MILNEZ medium at 35°C, which mimics the nasal environment of healthy individuals. They also showed that B. pertussis genes were differentially regulated by these conditions. Therefore, the present invention provides a new culture medium that mimics growth conditions in the nose. The new medium includes a source of carbon, nitrogen, salts, alkaline earth metals and specific transitions metals at concentrations close to those in mammalian nasal fluid cavity. The invention aims to improve the growth of Bordetella bacteria for vaccine production.

This invention provides a method for producing a freeze-dried vaccine containing attenuated Bordetella bacteria. [Solution] A method for producing a freeze-dried vaccine includes the steps of: collecting Bordetella bacteria from a culture; mixing the collected Bordetella bacteria with a freeze-drying buffer; freeze-drying the mixture of Bordetella bacteria and the freeze-drying buffer, wherein the holding time between the collection step and the freeze-drying step is less than 48 hours, and the freeze-drying step includes a pre-crystallization holding step, in which the mixture of Bordetella bacteria and the freeze-drying buffer is held for 0.5 to 10 hours at a temperature 0.1 to 10°C higher than the crystallization temperature of the mixture before further cooling; and collecting the freeze-dried Bordetella bacteria.

The present invention includes compositions, including epitope megapools, and methods for detecting the presence of: a Bordetella or an immune response relevant to a Bordetella infection including T cells responsive to one or more Bordetella peptides or proteins comprising, consisting of, or consisting essentially of: one or more amino acid sequences, fusion proteins, a pool of 2 or more peptides, or polynucleotides that expression the amino acid sequences selected from those set forth in any one of Tables 1-20 (SEQ ID NOS: 1 to 2598). The invention further provides vaccines, diagnostics, therapies, and kits, comprising such proteins or peptides.

To provide a vaccine for preventing pertussis capable of reducing asymptomatic Bordetella infection, in particular, asymptomatic B. pertussis infection (asymptomatic colonization).SOLUTION: A vaccine comprises a live attenuated Bordetella strain engineered to stably produce serotype 3 fimbriae (Fim3), where the live attenuated Bordetella strain retains the ability to colonize a mammalian subject's lungs and induce a protective immune response against Bordetella infection.SELECTED DRAWING: None